Navigation Links
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Date:10/19/2011

PARIS, October 20, 2011 /PRNewswire/ --

- New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress -

- U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS -

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization. A total of fifteen presentations on teriflunomide are on the program for the fifth joint triennial congress of the European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS / ACTRIMS) in Amsterdam, Netherlands.

The companies also announced today that the U.S. Food and Drug Administration has accepted for review Sanofi's new drug application (NDA) for oral teriflunomide as a potential therapy for people with relapsing forms of multiple sclerosis (MS).  Sanofi expects to file an application for regulatory approval with the European Medicines Agency (EMA) in the first quarter of 2012.

"The new results of the TEMSO study show that both 7mg and 14mg doses of teriflunomide could reduce the severity of relapses measured through annual rates of relapses leading to hospitalization as well as deliver encouraging long-term results on safety and efficacy," said Professor Paul O'Connor, Director of the MS Clinic at St. Michael's Hospital, Toronto, Canada, and principal investigator of the TEMSO study.

New post-hoc analyses showed that teriflunomide-treated patients' annualize
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
2. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
3. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
4. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
5. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
6. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
7. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
8. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
9. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
10. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
11. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... 2015 GenomeDx Biosciences today announced ... successfully classified various subtypes of bladder cancer ... biomarkers, including one type associated with resistance ... signature has potential as a tool to ... patients with muscle-invasive bladder cancers (MIBC). The ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
(Date:6/1/2015)... IL (PRWEB) June 01, 2015 ... developing and manufacturing of chiral stationary phases (CSPs) ... options for its current and presenting solutions for ... to its portfolio. This valuable addition to its ... and effective advantage that can tackle projects for ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... N.J., July 18, 2011 Insmed Incorporated ... Andrea ("Andi") Holtzman Drucker, J.D. has been appointed to ... Counsel and Corporate Secretary, effective as of July 18, ... Whitten, President and Chief Executive Officer of Insmed, will ...
... Today the Alzheimer,s Association® in conjunction with ... Global Perspective" panel discussion during the Alzheimer,s Association ... leaders in the Alzheimer,s field and revealed new ... findings explored the impact of Alzheimer,s disease on ...
... SAN DIEGO, July 15, 2011 Biocept, Inc. announced ... Senior Vice President, Finance and Chief Financial Officer.  As ... the company,s accounting, finance, treasury, investor relations, risk management ... years of leadership experience in helping to build life ...
Cached Biology Technology:Andrea Drucker Joins Insmed as General Counsel 2Andrea Drucker Joins Insmed as General Counsel 3Women at the Center of the Global Alzheimer's Epidemic 2Women at the Center of the Global Alzheimer's Epidemic 3Women at the Center of the Global Alzheimer's Epidemic 4Biocept, Inc. Announces New CFO 2Biocept, Inc. Announces New CFO 3
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... A research team led by U of T Mississauga scientists ... pair of cancer proteins, a finding that could ultimately lead ... effects. Working with scientists at the University of Central ... the Department of Chemical and Physical Sciences has created several ...
... has shown that the oldest complex life forms -- ... ago likely fed by osmosis. The researchers ... rangeomorphs and the air mattress-shaped erniettomorphs. These macroscopic organisms, ... outer membrane, much like modern microscopic bacteria, according to ...
... Researchers at the University of Oklahoma Health Sciences Center ... gene and high blood pressure. The results, which appear this ... on how we age and how we might live longer. ... factor for stroke, heart attack, heart failure, arterial aneurysm and ...
Cached Biology News:Disrupting a destructive duo: U of T Mississauga researchers inhibit cancer proteins 2Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 2Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 3Anti-aging gene linked to high blood pressure 2
... XS uniquely combines a single-channel sample processing ... 8-channel bulk reagent dispenser all in one ... using disposable pipette tips, the Precision XS ... dispenser is available for transferring larger volumes. ...
... ATP-Gamma-S binds to ATP-binding proteins. To ... FL fluorophore was linked through the ... its potential use for binding studies ... an important new substrate for Fhit ...
... of discovery races ever faster, you need a ... track. So our constant focus is on providing ... Thats why our Biomek 3000 Laboratory Automation Workstation ... as it is flexible. By integrating all aspects ...
... standard microarray image analysis software because of ... tools, visualizations, automation capabilities, performance and ease ... every GenePix scanner, and it also imports ... types of arrays. A wide range of ...
Biology Products: